PIK3CA and neoplasm: The ESMO rated PIK3CA mutation analysis with ESCAT scale IA [6] and in Germany, the recommendation for PIK3CA mutation profiling in primary tumor tissue, metastasis or plasma was confirmed in 2023 [148].